Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-03-14
2008-03-18
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100
Reexamination Certificate
active
07345026
ABSTRACT:
H-2 class I negative, HLA-A2.1 transgeniic HHD mice were used for a comparative evaluation of the immunogenicity of HLA-A2.1 restricted human tumor-associated CTL epitopes. A hierarchy was established among these epitopic peptides injected into mice in IFA which correlates globally with their capacity to bind and stabilize HLA-A2.1 molecules. Co-injection of a helper peptide enhanced most CTL responses. In contrast, classical HLA class I transgenic mice which still express their own class I molecules did not, in most cases, develop H.A.-A2.1-restricted CTL responses under the same experimental conditions. Different monoepitopic immunization strategies of acceptable clinical usage were compared in HHD mice. Recombinant Ty-virus-like particles, or DNA encoding epitopes fused to the hepatitis B virus middle envelope protein gave the best results. Using this latter approach and a melanoma-based polyepitope construct, CTL responses against five distinct epitopes could be elicited simultaneously in a single animal. Thus, HHD mice provide a versatile animal model for preclinical evaluation of peptide-based cancer immunotherapy.
REFERENCES:
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 5662907 (1997-09-01), Kubo et al.
patent: 5792463 (1998-08-01), Valenzuela et al.
patent: 5844075 (1998-12-01), Kawakami et al.
patent: 6133244 (2000-10-01), Michel et al.
patent: WO 95/22317 (1995-08-01), None
patent: WO9741440 (1997-11-01), None
patent: WO 99/46392 (1999-09-01), None
patent: WO 00/04149 (2000-01-01), None
Melegari et al. J. Virol. 1997, vol. 71, No. 7, pp. 5449-5454.
Shouval et al. Proc. Natl. Acad. Sci. USA, 1988, vol. 85, pp. 8276-8280.
Chen et al. Proc. Natl. Acad. Sci. 1996, vol. 93, pp. 1997-2001.
Conry et al. Clin. Caner Res. 1998, vol. 4, pp. 2903-2912.
Michel et al. Proc. Natl. Acad. Sci. USA, 1995, vol. 92, pp. 5307-5311. (A).
Michel et al. Proc. Natl. Acad. Sci. USA, 1988, vol. 85, pp. 7957-7961. (B).
Le Borgne et al. Virol. 1998, vol. 240, pp. 304-315.
Bryder et al. (DNA and Cell Biology, Mar. 1999, vol. 18, No. 3, pp. 219-225.
Toes et al. Proc. Natl. Acad. Sci. USA, 1997, vol. 94, pp. 14660-14665.
Schirmbeck et al. Eur. J. Immunol. 1999, vol. 29, pp. 1740-1749.
Schell et al. Cancer Research 2000, Viol. 61, pp. 873-879.
Arnold, B., et al., “MHC Class-1 Transgenic Mice”,Ann. Rev. Immunol. 9:297-322, 1991.
Bednarek, M.A., “The Minimum Peptide Epitope from the Influenza Virus Matrix Protein. Extra and Intracellular Loading of HLA-A2”,J. Immunol. 147(12):4047-4053, Dec. 15, 1991.
Burns, N.R., et al., “Production and Purification of Hybrid Ty-VLPs”,Mol. Biotechnol. 1(2):137-145, Apr. 1994.
Deres, K., et al., “In Vivo Priming of Virus-Specific Cytotoxic T Lymphocytes with Synthetic Lipopeptide Vaccine”,Nature342(6249):561-564, Nov. 30, 1989.
Falk, K., et al., “Allele-Specific Motifs Revealed by Sequencing of Self Peptides Eluted from MHC Molecules”,Nature351(6324):290-296, May 23, 1991.
Gao, G.F., et al., “Crystal Structure of the Complex Between Human CD8alpha(alpha) and HLA-A2”,Nature387:630-634, Jun. 5, 1997.
Hagen et al.P.N.A.S., 91:12808-12812, 1994.
Huang, A.Y., et al., “Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens”,Science264:961-965, May 13, 1994.
Inaba, K., et al., “Granulocytes, Macrophages, and Dendritic Cells Arise from a Common Major Histocompatability Complex Class II-Negative Progenitor in Mouse Bone Marrow”,Proc. Natl. Acad. Sci. USA90(7):3038-3042, Apr. 1, 1993.
Jakubezak et al.Cancer Res., 57:3606-3611, 1997.
Kalinke, U., et al., “Strong Xenogeneic H.A. Response in Transgenic Mice After Introducing an α3 Domain into H.A.-B27”,Nature348(6302):642-644, Dec. 13, 1990.
Kawakami, Y. and Rosenberg, S.A., “Human Tumor Antigens Recognized by T-Cells”,Immunol. Res. 16(4):313-339, Nov. 1997.
Layton, G.T., et al., “Introduction of Single and Dual Cytotoxic T-Lymphocyte Responses to Viral Proteins in Mice Using Recombinant Hybrid Ty-Virus-Like Particles”,Immunology87(2):171-178, Feb. 1996.
Le Borgne, S., et al., “In Vivo Induction of Specific Cytotoxic T Lymphocytes in Mice and Rhesus Macaques Immunized with DNA Vector Encoding an HIV Epitope Fused with Hepatitis B Surface Antigen”,Virology240(2):304-315, Jan. 20, 1998.
Mayordomo, J.L., et al., “Bone Marrow-Derived Dendritic Cells Pulsed with Synthetic Tumour Peptides Elicit Protective and Therapeutic Antitumour Immunity”,Nature Med. 1(12):1297-1302, Dec. 1995.
Melief, C. J., “Tumor Eradication by Adoptive Transfer of Cytotoxic T Lymphocytes”,Adv. Cancer Res.58:143-175, 1992.
Michel et al.P.N.A.S.92:5307-5311, 1995.
Milich, D.R., et al., “Hepatitis B Synthetic Immunogen Comprised of Nucleocapsid T-Cell Sites and an Envelope B-Cell Epitope”,Proc. Natl. Acad. Sci. USA85(5):1610-1614, Mar. 1988.
Momburg, F., et al., “Selectivity of MHC-Encoded Peptide Transporters from Human, Mouse and Rat”,Nature367(6464):648-651, Feb. 17, 1994.
Ossendorp, F., et al., “Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes Against Major Histocompatibility Complex Class II Negative Tumors”,J. Exp. Med. 187(5):693-702, Mar. 2, 1998.
Pascolo, S., et al., “H.A.-A2.1-Restricted Education and Cytolytic Activity of CD8+T Lymphocytes from β2 Microglobulin (β2m) H.A.-A2.1 Monochain Transgenic H-2Dbβ2m Double Knockout Mice”,J. Exp. Med. 185(12):2043-2051, Jun. 16, 1997.
PCT Search Report; PCT/EP 00/09900.
Porgador, A., et al., “Induction of Antitumor Immunity Using Bone Marrow-Generated Dendritic Cells”,J. Immunol.156(8):2918-2926, Apr. 15, 1996.
Rosenberg, S.A., et al., “Immunologic and Therapeutic Evaluation of a Synthetic Peptide Vaccine for the Treatment of Patients with Metastatic Melanoma”,Nature Med. 4(3):321-327, Mar. 1998.
Sette, A., et al., “The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes”,J. Immunol. 153(12):5586-5592, Dec. 1994.
Shirai, M., et al., “CTL Responses of H.A.-A2.1-Transgenic Mice Specific for Hepatitis C Viral Peptides Predict Epitopes for CTL of Humans Carrying H.A.-A2.1”,J. Immunol.154(6):2733-2742, Mar. 15, 1995.
Song, W., et al., “Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity”,J. Exp. Med. 186(8):1247-1256, Oct. 20, 1997.
Specht, J.M., et al., “Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective Against Established Pulmonary Metastases”,J. Exp. Med.186(8):1213-1221, Oct. 20, 1997.
Stoute et al., “A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine AgainstPlasmodium FalciparumMalaria”,The New England Journal of Medicine, 336(2);86-91, Jan. 1997.
Thomson, S.A., et al., “Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination”,J. Immunol.160(4):1717-1723, Feb. 15, 1998.
Tsomides, T.J., et al., “An Optimal Viral Peptide Recognized by CD8+T Cells Binds Very Tightly to the Restricting Class I Major Histocompatibility Complex Protein on Intact Cells But Not to the Purified Class I Protein”,Proc. Natl. Acad. Sci. USA88(24):11276-11280, Dec. 15, 1991.
van der Bruggen, P., et al., “A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma”,Science254:1643-1647, Dec. 13, 1991.
van der Burg, S.H., et al., “Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability”,J. Immunol.156(9):3308-3314, May 1, 1996.
Vasilakos, J.P. and Michael, J.G., “Herpes Simplex Virus Class I-Restricted Peptide Induces Cytotoxic T Lymphocytesin VivoIndependent of CD4+ T Cells”,J. Immunol.150(6):2346-2355, Mar. 15, 1993.
Vitiello,
Firat Hüseyin
Langlade-Demoyen Pierre
Lemonnier François
Michel Marie-Louise
Suhrbier Andreas A.
Campell Bruce R.
Finnegan Henderson Farabow Garrett & Dunner LLP
Institut Pasteur
Li Bao Qun
LandOfFree
Hybrid or chimeric polynucleotides, proteins, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hybrid or chimeric polynucleotides, proteins, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid or chimeric polynucleotides, proteins, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3979429